This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Daya, S.
Right arrow Articles by Berns, K. I.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Daya, S.
Right arrow Articles by Berns, K. I.

Next Article 

Clinical Microbiology Reviews, October 2008, p. 583-593, Vol. 21, No. 4
0893-8512/08/$08.00+0     doi:10.1128/CMR.00008-08
Copyright © 2008, American Society for Microbiology. All Rights Reserved.

Gene Therapy Using Adeno-Associated Virus Vectors

Shyam Daya1 and Kenneth I. Berns1,2*

Department of Molecular Genetics and Microbiology, College of Medicine,1 University of Florida Genetics Institute, University of Florida, Gainesville, Florida2

Summary: The unique life cycle of adeno-associated virus (AAV) and its ability to infect both nondividing and dividing cells with persistent expression have made it an attractive vector. An additional attractive feature of the wild-type virus is the lack of apparent pathogenicity. Gene transfer studies using AAV have shown significant progress at the level of animal models; clinical trials have been noteworthy with respect to the safety of AAV vectors. No proven efficacy has been observed, although in some instances, there have been promising observations. In this review, topics in AAV biology are supplemented with a section on AAV clinical trials with emphasis on the need for a deeper understanding of AAV biology and the development of efficient AAV vectors. In addition, several novel approaches and recent findings that promise to expand AAV's utility are discussed, especially in the context of combining gene therapy ex vivo with new advances in stem or progenitor cell biology.

* Corresponding author. Mailing address: P.O. Box 103610, University of Florida Genetics Institute, 1376 Mowry Road, Gainesville, FL 32610-3610. Phone: (352) 273-8072. Fax: (352) 273-8284. E-mail: kberns{at}ufl.edu

Clinical Microbiology Reviews, October 2008, p. 583-593, Vol. 21, No. 4
0893-8512/08/$08.00+0     doi:10.1128/CMR.00008-08
Copyright © 2008, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Buie, L. K., Rasmussen, C. A., Porterfield, E. C., Ramgolam, V. S., Choi, V. W., Markovic-Plese, S., Samulski, R. J., Kaufman, P. L., Borras, T. (2010). Self-complementary AAV Virus (scAAV) Safe and Long-term Gene Transfer in the Trabecular Meshwork of Living Rats and Monkeys. IOVS 51: 236-248 [Abstract] [Full Text]  
  • Schroen, B., Heymans, S. (2009). MicroRNAs and Beyond: The Heart Reveals Its Treasures. Hypertension 54: 1189-1194 [Full Text]  
  • Swinnen, M., Vanhoutte, D., Van Almen, G. C., Hamdani, N., Schellings, M. W.M., D'hooge, J., Van der Velden, J., Weaver, M. S., Sage, E. H., Bornstein, P., Verheyen, F. K., VandenDriessche, T., Chuah, M. K., Westermann, D., Paulus, W. J., Van de Werf, F., Schroen, B., Carmeliet, P., Pinto, Y. M., Heymans, S. (2009). Absence of Thrombospondin-2 Causes Age-Related Dilated Cardiomyopathy. Circulation 120: 1585-1597 [Abstract] [Full Text]  


Copyright © 2010 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»